Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30639135 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2APPKDM4EALDH1A1LMNA | |
| SCHEMBL31230012 | 0.84 | KDM4E (0.59) | SMN1; SMN2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL22435548 | 0.84 | KDM4E (0.59) | SMN1; SMN2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL21001348 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2APPKDM4EALDH1A1LMNA | |
| SCHEMBL28570899 | 0.81 | KDM4E (0.57) | SMN1; SMN2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL19787602 | 0.71 | APP (0.50) | SMN1; SMN2APPKDM4E | |
| SCHEMBL19787601 | 0.71 | APP (0.50) | SMN1; SMN2APPKDM4E | |
| SCHEMBL19787586 | 0.71 | APP (0.50) | SMN1; SMN2APPKDM4E | |
| SCHEMBL21001388 | 0.69 | SMN1; SMN2 (0.39) | SMN1; SMN2APPKDM4EALDH1A1LMNA | |
| SCHEMBL4905237 | 0.69 | KDM4E (0.40) | SMN1; SMN2KDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415369-B | Fused pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-109311877-B | Fused pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3481829-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-04-07 | — | — | EP | disclosed |
| EP-3484884-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10730881-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| CN-111315739-A | Pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2020-06-19 | — | — | CN | disclosed |
| US-10669276-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190256517-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2018011164-A1 | FUSED PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730881-B2 | Fused pyrimidine derivatives | APP, UPF1, PSEN1 | SMN1; SMN2 1523/4885APP 1/4885KDM4E 4705/4885 |
| US-20190256517-A1 | FUSED PYRIMIDINE DERIVATIVES | C9, APP, HPGDS | SMN1; SMN2 2364/4885APP 2/4885KDM4E 4568/4885 |
| US-10669276-B2 | Fused pyrimidine derivatives | APP, APOB, C9 | SMN1; SMN2 2483/4885APP 1/4885KDM4E 4495/4885 |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | APP, UPF1, PSEN1 | SMN1; SMN2 1523/4885APP 1/4885KDM4E 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.